It's interesting that the FDA approved this one (and given the sensitivities around Testosterone drug at the moment it is significant). Haven't looked into the detail yet, but could have scared some holders?
On the Morningstar research - i only have access to the Analyst Note dated 03/04/2014 (published in this thread). Although i have a US subscription so not sure i get to see all the Australian stuff.
I certainly don't believe that there was anything in the MS note to "move the market" as inferred by the AFR - think the reference is clutching at straws...
Regards, Mite
ACR Price at posting:
$1.98 Sentiment: LT Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)